AbbVie invests $223 million in Singapore manufacturing site to expand biologics manufacturing capacity
– US$223 million expansion adds biologics production capacity to AbbVie’s manufacturing network
– Singapore manufacturing base expands to more than 500 employees
– Construction is expected to begin immediately and the facility is expected to be operational in 2026
Singapore January 26, 2024 – AbbVie (NYSE: ABBV) on Thursday broke ground on a new US$223 million (S$301 million) expansion of its manufacturing facility in Singapore, increasing its manufacturing capacity. This new investment will add more than 100 jobs and new biologics manufacturing capacity to AbbVie’s global network.
AbbVie’s Singapore facility, located in Singapore’s Tuas Biomedical Park, is a state-of-the-art small molecule and biologics manufacturing facility serving markets around the world. This new investment will add 24,000 liters of biologic drug substance production capacity to AbbVie’s global manufacturing network, supporting current products as well as new immunology and oncology compounds in AbbVie’s pipeline. It will be.
 |
|
Officials from AbbVie and the Singapore Economic Development Board attended the groundbreaking ceremony for AbbVie’s $223 million Singapore manufacturing expansion on January 25. Once completed, the new expansion will add new biologics manufacturing capacity to AbbVie’s global network and create more than 100 new jobs in Singapore.
|
“This expansion announcement is one of many investments in AbbVie’s Singapore-based operations and represents a proud continuation of our 10-year partnership with the Singapore government.” said Dr. Ajita Saleki Gerhardt, Vice President and Chief. Operations officer. “The expansion of our Singapore site strengthens our global manufacturing capabilities, supports our growing biologics pipeline, and enables AbbVie to continue delivering on its commitment to patients now and in the future. Become.”
With today’s announcement, AbbVie has invested more than US$740 million (S$1 billion) in the acquisition, modernization and expansion of its Singapore facilities over the past decade. Once fully operational, AbbVie’s expanded Singapore manufacturing facility, AbbVie’s only manufacturing site in Asia, will employ more than 500 employees in manufacturing, quality assurance, supply chain, engineering, and management roles. .
“We are pleased that AbbVie has chosen to expand its biopharmaceutical manufacturing capacity in Singapore for current and future innovative medicines. We are grateful for their continued confidence in our strength. AbbVie’s investment will strengthen Singapore’s cutting-edge manufacturing ecosystem and create exciting job opportunities here.” said Cindy Ko, executive vice president of the association.
Expansion work is expected to begin later this year, with operations expected to begin in 2026. AbbVie’s Singapore manufacturing facility is part of AbbVie’s operations team, which is comprised of 14,000 employees working in more than 30 manufacturing, operations and distribution locations across the United States. , Asia, Europe, Puerto Rico, and South America.
About AbbVie
AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve today’s serious health problems and address tomorrow’s healthcare challenges. We strive to make a significant impact on people’s lives across several key therapeutic areas, including immunology, oncology, neuroscience and eye care, as well as the products and services of our Allergan Aesthetics portfolio. For more information about AbbVie, please visit www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, and Instagram. X (old Twitter)YouTube.
media contact
John Torrisi
+1 (224) 213-0055
John.Torrisi@abbvie.com
Kim Yoo-sook
+82 (02) 3429 9296
Yoosook.Kim@abbvie.com